News

Sobi and Biogen success in Phase III
Enlarge image

BusinessSweden

Sobi and Biogen success in Phase III

27.09.2012 - Swedish Sobi and Biogen Idec have proved safety and efficacy of a haemophila B drug that prevents bleeding three times longer than other clotting factors.

In the B-LONG Phase III study on 126 haemophila B patients, the partners proved safety and efficacy of their long-lasting recombinant Factor IX Fc fusion protein (rFIXFc). According to the companies, 90.4% of bleeding episodes were controlled by a single shot of  the engineered clotting factor and showed only one serious adverse effect possibly related to the product.  Biogen Idec plans to submit a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) in the first half of 2013. Filing in Europe will require completion of the ongoing Kids B-LONG study in children less than 12 years.

The top line results are good news for the Swedish drug maker, which had to restructure last year due to loss in revenues. According to pharmacokinetic (PK) analysis terminal half-life of the fusion protein of Factor IX and the Fc domain of human IgG(1) was 82 hours compared to 34 hours for BeneFIX.“Our companies are pioneering the application of Fc fusion technology to extend the half-life of clotting factors. Fc fusion technology utilises a naturally-occurring recycling pathway that has been successfully employed in other therapeutic areas. This approach holds promise for combining more consistent protection with fewer injections,” said Sobi CEO Geoffrey McDonough.

The B-LONG study had four treatment arms: weekly prophylaxis, individualised interval prophylaxis, episodic treatment and perioperative management (Arms 1, 2, 3 and 4, respectively). 93.5 percent of patients completed the study. Recombinant FIXFc was generally well-tolerated. No inhibitors to rFIXFc were detected and no cases of anaphylaxis were reported in any patients. The overall median annualised bleeding rates (including spontaneous and traumatic bleeds) were 2.95 in the weekly prophylaxis arm, 1.38 in the individualised interval prophylaxis arm, and 17.69 in the episodic treatment arm. In the individualised interval prophylaxis arm, the median dosing interval during the last 6 months on study was 14 days. 

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-03/sobi-and-biogen-success-in-phase-iii.html

AwardFinlandEU

27.05.2016 The Finnish Technology Academy has awarded US-American innovator Frances Arnold the 2016 Millennium Technology Prize, worth €1m. Arnold is a pioneer in the field of directed evolution.

OncologyUK

26.05.2016 BigDNA relaunches as Iceni Pharmaceuticals with the aim to develop repurposed and reformulated cancer therapies. First order of business: repurpose Merck Serono’s cilengitide as a multiple myeloma treatment.

MicrobiomeFranceDenmarkEU

24.05.2016 One of the pioneering companies developing pharmaceuticals and diagnostics based on the gut microbiome, Enterome Bioscience, has raised €14.5m in a Series C financing round. Among the investors were Seventure and Lundbeckfond as well as Nestlé.

AntibioticsEUUKItaly

20.05.2016 The long awaited global review on antimicrobial resistance by economist Lord Jim O’Neill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.

LicensingGermanyIrelandSwitzerland

18.05.2016 Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.

M&AGermany

17.05.2016 Newly rebranded Siemens Healthcare has entered the field of molecular testing for cancers with the acquisition of Cologne-based NEO New Oncology.

FinancingUK

11.05.2016 Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.

FinancingSwitzerland

09.05.2016 Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimer’s disease. The news follows a recently announced R&D collaboration with Biogen.

FinancingSpain

04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

Open InnovationFrance

03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Aachen

Biomedica 2016

Basel (CH)

Chemspec Europe 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • 4SC (D)3.25 EUR8.33%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)5.50 SEK-7.56%
  • RENEURON (UK)3.50 GBP-5.41%
  • OXFORD BIOMEDICA (UK)5.62 GBP-4.91%

TOP

  • THERAMETRICS (CH)0.03 CHF50.0%
  • GALAPAGOS (B)52.00 EUR29.9%
  • NICOX (F)10.91 EUR26.6%

FLOP

  • BIONOR PHARMA (N)0.68 NOK-23.6%
  • MOBERG PHARMA (S)38.60 SEK-22.0%
  • BIOCARTIS GROUP NV (B)8.15 EUR-20.1%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)31.00 SEK1953.0%
  • NICOX (F)10.91 EUR486.6%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)5.50 SEK-88.8%
  • BB BIOTECH (D)43.82 EUR-84.9%
  • BIOTEST (D)17.14 EUR-77.7%

No liability assumed, Date: 26.05.2016